No-Cost, No-Obligation Onglyza Lawsuit Case Review

Onglyza Attorneys

Onglyza Heart Attack

Persons Diagnosed with Heart Failure from Onglyza: Onglyza Heart Disease and Who is Eligible to File an Onglyza Lawsuit

Onglyza Heart Failure

Onglyza, a popular drug prescribed to regulate blood glucose levels in Type II diabetics, has been linked to an increased rate of heart failure. After seven years on the market, an Onglyza heart failure warning was added to the product label in April of 2016. Persons and family members of persons who have suffered from heart attack, heart disease, or heart failure while taking Onglyza may have legal grounds to file an Onglyza heart disease lawsuit.

About Onglyza

Onglyza (saxagliptin) is a DPP-4 (dipeptidyl peptidase-4) inhibitor drug that is used in tandem with diet and exercise to regulate blood glucose levels in patients suffering from Type II diabetes. Onglyza lowers the body’s blood sugar by helping to increase levels of the hormone insulin after meals. When insulin is present, the body can make use of sugars as a form of energy, thus keeping blood sugar levels stable.

More than 20 million people are living with a diagnosis of diabetes in the United States. In 2015, approximately 386,000 patients were dispensed with Onglyza or a similar drug containing the same active ingredients. Prior to the release of Onglyza heart disease information, the drug became a popular choice in the United States. For patients diagnosed with Type II diabetes who do not suffer from ketoacidosis, Onglyza is popular because of its effectiveness and because it does not result in weight gain, as many other glucose regulators do.

Onglyza is marketed by the British-Swedish pharmaceutical company AstraZeneca. It was approved by the FDA for use in the United States in 2009. Annual sales of Onglyza reached $786 million in 2015, and were projected to expand to $2.47 billion by 2018. AstraZeneca has been aware of the Onglyza heart attack risk since a study on the subject was published in 2013, yet the company waited until 2016 to add a heart failure warning to Onglyza labels when ordered to do so by the FDA.

Onglyza Heart Disease

The Onglyza Heart Failure Risk

Information on Onglyza heart failure has only recently been made widely available to the public. The FDA now warns that taking Onglyza results in an increased risk of heart failure and heart attack in patients, as compared to Type II diabetics with a similar risk profile who are not taking Onglyza.

Heart failure indicates the onset of heart disease, a worsening of heart disease, or an acute incident such as heart attack. Heart failure is simply defined as a condition in which the heart is not able to pump enough blood to meet the needs of the body.

A new Onglyza heart failure warning on the drug’s label warns that patients taking Onglyza who experience symptoms of heart disease or suspect heart attack should seek medical help. Onglyza heart failure signs include shortness of breath, tiredness, fatigue, weakness, trouble breathing while lying down, heart palpitations, faster heartbeat than normal, dizziness, faintness, lightheadedness, and weight gain with swelling in the ankles, feet, legs, or stomach.

Patients taking Onglyza who experience any of these symptoms should contact their doctor immediately to be assessed for Onglyza heart disease. The FDA has advised doctors that “if heart failure develops” in patients taking Onglyza, they should “consider discontinuing the drug”.

Onglyza Heart Attack Research

The results of a prominent Onglyza heart failure study, SAVOR-TIMI 53, were published in the New England Journal of Medicine in 2013. Entitled “Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus”, the NEJM article outlines the outcomes of the large, randomized study that tracked more than 16,000 over the course of 2-3 years. The study indicated that patients taking Onglyza to assist in the control of blood glucose levels face a risk of hospitalization for heart failure that is 1.27 times higher than that of diabetics not taking Onglyza, an increase of 27%. In addition, the study determined that patients taking Onglyza have higher natriuretic peptide levels than patients taking a placebo, which is an indicator for future heart disease and heart failure.

Let Our Onglyza Heart Attack Lawyers Help You

Our attorneys specialize in holding large corporations accountable when they have prioritized profits ahead of safety. Through settlements and winning verdicts, our attorneys have obtained millions for our clients. Let us help you today.

Onglyza Heart Disease Lawsuits

Filing a lawsuit will allow you to hold the pharmaceutical company accountable for damage it has caused you or a loved one, while also providing real compensation for your medical expenses, suffering and loss. Contact us today for a free consultation.